It is a GLP-1 receptor agonist with structural modifications, including a fatty-acid side chain, that extend its half-life enough to support once-weekly dosing
Please note: All products at Pivot Labs are intended ONLY for research purposes and must not be used for any other purpose whatsoever
Featured Expert Mark Graber, JD Carey School of Law Source: WBAL Radio More Thyroid Cancers Found After Starting GLP-1s: Researchers Think They Know Why January 24, 2025 Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas (HR 1.85, 95% CI 1.11-3.08), reported Rozalina McCoy, MD, MS, of the University of Maryland School of Medicine in Baltimore, and colleagues
Clinical trial enrollment offers the highest quality access but the least predictability